<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02233543</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149ANO01</org_study_id>
    <nct_id>NCT02233543</nct_id>
  </id_info>
  <brief_title>A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a fixed dose combination of indacaterol
      and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in Chronic
      Obstructive Pulmonary Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean night-time blood oxygenation</measure>
    <time_frame>Measured after 4 weeks administration of QVA149 or placebo</time_frame>
    <description>The mean night-time blood oxygenation following 4 weeks administration of QVA149 compared to placebo will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time during the night spent below 90 % in blood oxygen saturation</measure>
    <time_frame>Measured after 4 weeks administration of QVA149 or placebo</time_frame>
    <description>The time during the night spent below 90 % in blood oxygen saturation following 4 weeks administration of QVA149 compared to placebo will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>QVA149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149</intervention_name>
    <description>Delivered once daily via single-dose dry powder inhaler</description>
    <arm_group_label>QVA149</arm_group_label>
    <other_name>indacaterol</other_name>
    <other_name>glycopyrronium</other_name>
    <other_name>Ultibro Breezhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149 Placebo</intervention_name>
    <description>Placebo delivered once daily via single-dose dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of COPD (according to GOLD guidelines, updated 2014) with a
             post-bronchodilator FEV1/FVC &lt;0.70

          -  Patients with a post-bronchodilator FEV1 ≥30% and &lt;60% of the predicted normal value

          -  Resting daytime oxygen saturation levels measured by pulse oximetry of ≤95% SpO2

          -  Smoking history of at least 10 pack years (Ten pack-years are defined as 20
             cigarettes a day for 10 years, or 10 cigarettes a day for 20 years)

        Exclusion Criteria:

          -  An exacerbation of COPD (treatment with oral or parenteral antibiotics and/or
             glucocorticosteroids and/or hospitalization related to COPD) within 4 weeks prior to
             screening or during the run-in period

          -  Diagnosed asthma

          -  Patients receiving regular long term oxygen therapy (LTOT)

          -  Ongoing / planned rehabilitation during the study period

          -  Three or more awakenings during the night leading to toilet visit or other reasons
             for exiting the bed during the last week prior to the screening visit due to non-COPD
             reasons

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>-N5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 8, 2016</lastchanged_date>
  <firstreceived_date>August 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>QVA149</keyword>
  <keyword>nocturnal oxygen levels</keyword>
  <keyword>combination bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
